Publication Details
Abstract
Cancer is a multifaceted disease characterized by profound metabolic reprogramming, which enables tumor cells to sustain rapid proliferation, evade apoptosis, and adapt to microenvironmental stresses. Metabolic biomarkers have emerged as critical tools for understanding tumor biology, aiding in early diagnosis, monitoring disease progression, and guiding therapeutic interventions. This review explores the role of metabolic biomarkers in linking altered cellular metabolism to tumor progression and therapeutic targeting. Hallmarks of cancer metabolism, such as the Warburg effect, glutaminolysis, and lipid metabolism dysregulation, produce distinct metabolic byproducts that serve as potential biomarkers. Key metabolites, including lactate, glutamine, and lipid derivatives, reflect the metabolic demands of tumor cells and their interaction with the tumor microenvironment. Advances in metabolomics and imaging techniques have facilitated the identification of these biomarkers, providing insights into tumor heterogeneity and metabolic vulnerabilities. Moreover, metabolic biomarkers are increasingly being utilized to predict treatment response and resistance. For instance, elevated levels of lactate and hypoxia-inducible factor-1α (HIF-1α) correlate with poor prognosis and resistance to conventional therapies. Targeting metabolic pathways, such as glycolysis inhibitors or glutaminase inhibitors, has shown promise in preclinical and clinical studies, underscoring the therapeutic potential of disrupting tumor metabolism. This review highlights the clinical utility of metabolic biomarkers as diagnostic and prognostic tools, while also emphasizing their role in developing targeted therapies. By integrating metabolic profiling into precision oncology, these biomarkers hold the potential to improve patient outcomes and personalize cancer treatment strategies. Further research is essential to validate their application across diverse cancer types and therapeutic settings.